BioMarin Pharmaceutical | BMRN - Loan Capital



BioMarin Pharmaceutical reported $596.16M in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 1.03B 956K Jun/2025
Amgen USD 53.76B 253M Jun/2025
Bayer EUR 31.71B 3.31B Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
Incyte USD 31.76M 883K Jun/2025
Insmed USD 560.95M 567.39M Jun/2025
Ionis Pharmaceuticals USD 625.49M 625.22M Jun/2025
Moderna USD 32M 3M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
PTC Therapeutics USD 2.13B 1.85B Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
Sanofi 14.72B 2.93B Jun/2025
Sarepta Therapeutics USD 1.14B 1.17M Jun/2025
Ultragenyx Pharmaceutical USD 782.75M 782.75M Jun/2025
United Therapeutics USD 0 0 Mar/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024